Institutional analyst coverage and formal consensus ratings for Assertio (ASRT) shifted over time in response to quarterly financial results, portfolio restructuring, and changing product revenues. Following the completion of the all-cash acquisition agreement by Zydus Lifesciences, which resulted in the company becoming a private, wholly-owned subsidiary and the subsequent delisting of its shares from the Nasdaq, active public equity analyst ratings are no longer applicable.